Sugi Predict

Sugi Predict / Compounds / SCHEMBL18763039

SCHEMBL18763039

SCHEMBL18763039

C=CC(=O)N(c1ccccc1)C1CCCCC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPM8 Q7Z2W7 6/20 0.67
▸ ALDH1A1 P00352 2/20 0.59
▸ SMN1; SMN2 Q16637 2/20 0.59
▸ KDM4E B2RXH2 1/20 0.59
▸ MEN1 O00255 1/20 0.59
▸ NPC1 O15118 1/20 0.59
▸ MITF O75030 1/20 0.59
▸ RAB9A P51151 1/20 0.59
▸ KMT2A Q03164 1/20 0.59
▸ PAX8 Q06710 1/20 0.59
▸ CHRM2 P08172 1/20 0.43
▸ CHRM3 P20309 1/20 0.43
▸ LMNA P02545 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ ENPP2 Q13822 1/20 0.41
▸ ESR1 P03372 1/20 0.41
▸ NPY2R P49146 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ MLYCD O95822 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6215102 0.81 KDM4E (0.68) TRPM8ALDH1A1SMN1; SMN2KDM4EMEN1
SCHEMBL13681388 0.81 TRPM8 (0.46) TRPM8ALDH1A1SMN1; SMN2KDM4EMEN1
SCHEMBL11500743 0.81 TRPM8 (0.46) TRPM8ALDH1A1SMN1; SMN2KDM4EMEN1
SCHEMBL1699149 0.80 TRPM8 (1.00) TRPM8ALDH1A1SMN1; SMN2KDM4EMEN1
SCHEMBL9862213 0.80 TRPM8 (0.48) TRPM8ALDH1A1SMN1; SMN2KDM4EMEN1
SCHEMBL1699151 0.80 TRPM8 (1.00) TRPM8ALDH1A1SMN1; SMN2KDM4EMEN1
SCHEMBL2395969 0.80 ALDH1A1 (0.66) TRPM8ALDH1A1SMN1; SMN2KDM4EMEN1
SCHEMBL11407980 0.79 MEN1 (0.65) TRPM8ALDH1A1SMN1; SMN2KDM4EMEN1
SCHEMBL11579712 0.79 TRPM8 (0.44) TRPM8ALDH1A1SMN1; SMN2KDM4EMEN1
SCHEMBL6601536 0.78 KDM4E (0.64) TRPM8ALDH1A1SMN1; SMN2KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240131032-A1 AN ACTIVITY-GUIDED MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS THE SCRIPPS RESEARCH INSTITUTE 2024-04-25 — — US disclosed
US-20240123078-A1 COMPOUNDS AND METHODS FOR MODULATING IMMUNE-RELATED PROTEINS VIVIDION THERAPEUTICS, INC. 2024-04-18 — — US disclosed
US-11795353-B2 Adhesive composition NIPPON SODA CO., LTD. (JP) 2023-10-24 — — US disclosed
US-11795353-B2 Adhesive composition NIPPON SODA CO., LTD. (JP) 2023-10-24 — — US disclosed
US-20220298213-A1 IN VIVO ENGINEERED CEREBLON PROTEIN VIVIDION THERAPEUTICS, INC. 2022-09-22 — — US disclosed
EP-4045050-A1 AN ACTIVITY-GUIDED MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS The Scripps Research Institute (US) 2022-08-24 — — EP disclosed
CN-113956175-A Adhesive composition 日本曹达株式会社 2022-01-21 — — CN disclosed
US-20210284879-A1 ADHESIVE COMPOSITION NIPPON SODA CO., LTD. (JP) 2021-09-16 — — US disclosed
WO-2021076755-A1 AN ACTIVITY-GUIDE MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS THE SCRIPPS RESEARCH INSTITUTE (US) 2021-04-22 — — WO disclosed
WO-2021076755-A1 AN ACTIVITY-GUIDE MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS THE SCRIPPS RESEARCH INSTITUTE (US) 2021-04-22 — — WO disclosed
US-20190216893-A1 COMPOSITIONS AND METHODS OF MODULATING IMMUNE RESPONSE THE SCRIPPS RESEARCH INSTITUTE 2019-07-18 — — US disclosed
US-20190216893-A1 COMPOSITIONS AND METHODS OF MODULATING IMMUNE RESPONSE THE SCRIPPS RESEARCH INSTITUTE 2019-07-18 — — US disclosed
CN-109804033-A Adhesive composition 日本曹达株式会社 2019-05-24 — — CN disclosed
EP-3365686-A1 CYSTEINE REACTIVE PROBES AND USES THEREOF The Scripps Research Institute (US) 2018-08-29 — — EP disclosed
WO-2017205972-A1 SYSTEMS METHODS AND COMPOSITIONS FOR PREDICTING METASTASIS IN BLADDER CANCER GENOMEDX BIOSCIENCES, INC. (CA) 2017-12-07 — — WO disclosed
US-20170115303-A1 CYSTEINE REACTIVE PROBES AND USES THEREOF THE SCRIPPS RESEARCH INSTITUTE 2017-04-27 — — US disclosed
WO-2017070611-A1 CYSTEINE REACTIVE PROBES AND USES THEREOF THE SCRIPPS RESEARCH INSTITUTE (US) 2017-04-27 — — WO disclosed
WO-2017070611-A1 CYSTEINE REACTIVE PROBES AND USES THEREOF THE SCRIPPS RESEARCH INSTITUTE (US) 2017-04-27 — — WO disclosed
US-20170115303-A1 CYSTEINE REACTIVE PROBES AND USES THEREOF THE SCRIPPS RESEARCH INSTITUTE 2017-04-27 — — US disclosed
US-20170115303-A1 CYSTEINE REACTIVE PROBES AND USES THEREOF THE SCRIPPS RESEARCH INSTITUTE 2017-04-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220298213-A1 IN VIVO ENGINEERED CEREBLON PROTEIN CRBN, CDR2, DCUN1D4 TRPM8 4874/4885ALDH1A1 2798/4885SMN1; SMN2 2207/4885
US-20240123078-A1 COMPOUNDS AND METHODS FOR MODULATING IMMUNE-RELATED PROTEINS CD4, ICOS, NFATC1 TRPM8 2260/4885ALDH1A1 4719/4885SMN1; SMN2 4469/4885
US-20190216893-A1 COMPOSITIONS AND METHODS OF MODULATING IMMUNE RESPONSE IFNG, MYD88, ICOS TRPM8 3661/4885ALDH1A1 4498/4885SMN1; SMN2 3849/4885
US-20240131032-A1 AN ACTIVITY-GUIDED MAP OF ELECTROPHILE-CYSTEINE INTERACTIONS IN PRIMARY HUMAN IMMUNE CELLS GSTK1, GSTA2, GSTA1 TRPM8 3096/4885ALDH1A1 1423/4885SMN1; SMN2 4743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback